Synthesis and Biological Response of Size-Specific, Monodisperse Drug–Silica Nanoconjugates
Citations Over TimeTop 1% of 2012 papers
Abstract
Drug-containing nanoparticles (NPs) with monodisperse, controlled particle sizes are highly desirable for drug delivery. Accumulating evidence suggests that NPs with sizes less than 50 nm demonstrate superior performance in vitro and in vivo. However, it is difficult to fabricate monodisperse, drug-containing NPs with discrete sizes required for studying and characterizing existing relationships among particle size, biologic processing, and therapeutic functionality. Here, we report a scalable process of fabricating drug-silica conjugated nanoparticles, termed drug-silica nanoconjugates (drug-NCs), which possess monodisperse size distributions and desirable particle sizes as small as 20 nm. We find that 20 nm NCs are superior to their 50 and 200 nm NC analogues by 2-5- and 10-20-fold, respectively, with regard to tumor accumulation and penetration and cellular internalization. These fundamental findings underscore the importance and necessity of further miniaturizing nanomedicine size for optimized drug delivery applications.
Related Papers
- → Dispersity in polymer science (IUPAC Recommendations 2009)(2009)306 cited
- → Dispersity in polymer science (IUPAC Recommendation 2009)(2009)33 cited
- → Distribution of near neighbours in randomly packed hard spheres(1980)8 cited
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)
- → Dispersity in Polymer Science(2016)